iBio Inc announced an update to its corporate presentation on October 23, 2024, showcasing its transformation into an AI-driven antibody discovery company. The presentation highlights their proprietary machine learning antibody engine for creating first-in-class and best-in-class therapeutics.The company's technology stack includes patented epitope-steering technology, StableHu antibody optimizer with mammalian display, EngageTx next-generation bi-specific antibody platform, and ShieldTx antibody masking. The pipeline features six preclinical programs targeting hard-to-drug molecules, with promising early CMC development data for lead asset IBIO-101.iBio has established multiple strategic partnerships, including collaborations with Eli Lilly, NIH, and AstralBio, demonstrating platform validation. The company's recent expansion into cardiometabolic diseases through the AstralBio partnership marks a significant strategic advancement in their therapeutic focus.

iBio Inc announced an update to its corporate presentation on October 23, 2024, showcasing its transformation into an AI-driven antibody discovery company. The presentation highlights their proprietary machine learning antibody engine for creating first-in-class and best-in-class therapeutics.The company's technology stack includes patented epitope-steering technology, StableHu antibody optimizer with mammalian display, EngageTx next-generation bi-specific antibody platform, and ShieldTx antibody masking. The pipeline features six preclinical programs targeting hard-to-drug molecules, with promising early CMC development data for lead asset IBIO-101.iBio has established multiple strategic partnerships, including collaborations with Eli Lilly, NIH, and AstralBio, demonstrating platform validation. The company's recent expansion into cardiometabolic diseases through the AstralBio partnership marks a significant strategic advancement in their therapeutic focus.